Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density
Portfolio Pulse from
Atossa Therapeutics has announced full results from its Phase 2 KARISMA-Endoxifen study, showing that a 1 MG dose of (Z)-Endoxifen significantly reduces mammographic breast density. This suggests potential as a preventative therapy for premenopausal women at risk of breast cancer.
December 11, 2024 | 1:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Atossa Therapeutics' Phase 2 study results show that (Z)-Endoxifen significantly reduces mammographic breast density, indicating its potential as a preventative therapy for breast cancer.
The positive results from the Phase 2 study of (Z)-Endoxifen suggest a promising new preventative therapy for breast cancer, which could lead to increased investor interest and a potential rise in Atossa's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100